Sonida Senior Living, Inc. Announces Second Quarter 2022 Results
DALLAS–(BUSINESS WIRE)–$SNDA–Sonida Senior Living, Inc. (the “Company,” “we,” “our,” or “us”) (NYSE: SNDA) announced results…
DALLAS–(BUSINESS WIRE)–$SNDA–Sonida Senior Living, Inc. (the “Company,” “we,” “our,” or “us”) (NYSE: SNDA) announced results…
Oslo, 12 August 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune…
Geneva, Switzerland, August 12, 2022 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical…
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to…
HONG KONG, Aug 12, 2022 – (ACN Newswire) – As the effects of the pandemic…
SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
LSIGraph revamped its current toolsets in the latest upgrade and introduced new SEO features to…
Vancouver, British Columbia–(Newsfile Corp. – August 11, 2022) – Axion Ventures Inc. (TSXV: AXV) (the “Company” or…
HONG KONG, Aug 12, 2022 – (ACN Newswire) – Yunkang Group Limited (“Yunkang” or the…
Forms joint venture with a subsidiary of the largest private sector electric distribution utility company…
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected…
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from…
One Immortl One Immortl MUNICH, Germany , Aug. 12, 2022 (GLOBE NEWSWIRE) — The One…
SAN DIEGO–(BUSINESS WIRE)–$TUYA #TUYA—The Class: Shareholder rights law firm Robbins LLP informs investors that a…
FG Financial Group Sees Reinsurance Premium Growth As It Continues to Expand Its Reinsurance Business…
Completed business combination with Social Capital Suvretta Holdings, III WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE…
Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from…
Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103…
BUENOS AIRES, Argentina–(BUSINESS WIRE)–Loma Negra, (NYSE: LOMA; BYMA: LOMA), (“Loma Negra” or the “Company”), the…